Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Prospective, Phase II, Single-arm Study to Evaluate The Safety and Efficacy of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen

NCT05138159 is registered in ClinicalTrials.gov with Fudan University as lead sponsor.

NCT NCT05138159
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05138159 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Prospective, Phase II, Single-arm Study to Evaluate The Safety and Efficacy of Donafenib Plus S-1 in Treating Patients With Metastatic Pancreatic Cancer After Chemotherapy With Nab-paclitaxel Plus Gemcitabine Regimen
Lead sponsor
Fudan University
Phase
Phase 2
Overall status
Unknown status
Start date
December 1, 2021
Completion date
July 30, 2023
Enrollment
10 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

metastatic pancreatic cancer